| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2928200 | Indian Heart Journal | 2012 | 6 Pages |
Abstract
Both prasugrel and ticagrelor are more potent than clopidogrel. The data so far suggests that ticagrelor has a wider applicability in usage in patients with ACS as compared to prasugrel. Prasugrel however seems to be better tolerated. Search is on for newer more potent but safer anti-platelet agents.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Upendra Kaul, Aijaz H. Mansoor,